Home > Healthcare IT > Global Uterine Cancer Market Size, Share and trends Outlook To 2026
Straits Research

Uterine Cancer Market

Uterine Cancer Market: Information by Type, Treatment, End User (Hospitals, Diagnostic Center, Online Pharmacies), and Region — Forecast till 2026

Table of Content Download Sample

Market Overview

Global endometrial cancer market is expected to register a CAGR of 4.7% over the forecast period 2019-2026.

Women of age between 42 and 50 experiencing menopause or post menopause, are more susceptible to be diagnosed and suffer through uterine cancer. It starts in the endometrium, which is a lining of uterus and proceeds to uterus and neighboring tissues and then to the whole body. Exact causes of the uterine cancer is still unknown and early diagnosis is roughly possible due to very common symptoms such as casual bleeding and others. Among four types of the uterine cancer, papillary serous carcinoma is most dangerous and aggressive as it tends to return even when it is diagnosed early and treated. Moreover, uterine sarcoma starts in the myometrium, uterine muscle wall and spreads to whole uterus and it tends to spread to lungs through bloodstream.

High and increasing prevalence of the uterine cancer is the major factor driving the global uterine cancer market. According to the World Cancer Research Fund International, prevalence rate of the uterine cancer per 100,000 women is high across the globe in major countries including Belarus has 24.9 rate, Samoa has 24.8, Canada has 23.6, the U.S. 20.1, Poland has 19.1, Singapore has 19.1, Russia has 18.7, and Puerto Rico has 17.4. Ongoing research and development regarding diagnostics and treatment of the uterine cancer is the other factor which is expected to escalate the market growth during the forecast period 2019–2026.

However, poor healthcare infrastructure across the Latin America and Africa is expected to restrain the market growth. Lack of advancements in the diagnostics in some region and scarcity of skilled diagnostics professionals are some of the other factors which are expected to hamper the market growth further. Unavailability of the reimbursement policies may slow the market growth during the forecast period 2019–2026.

Market Snapshot

market snapshot
Base Year
: 2017
Study Period
: 2016-2026
CAGR
: 4.7 %
Fastest Growing Market
: Europe
Largest Market
: North America
Market Size
: 620
Get more information on this report Download Sample Report

Segmental Analysis

The global uterine cancer market is segmented into type, treatment, end user, and region.

Based on type

The global uterine cancer market is segmented into endometrial adenocarcinoma, adenosquamous carcinoma, papillary serous carcinoma, and uterine sarcoma. Amongst type, endometrial adenocarcinoma segment accounts for major share of the global uterine cancer market. Adenosquamous carcinoma is expected to grow steadily during the forecast period 2019–2026.

On the basis of treatment

The market is segmented into diagnosis, therapeutic treatment, and surgery. Diagnosis is further segmented into Pelvic examination, endometrial biopsy, transvaginal ultrasound, computed tomography (CT or CAT) scan, and magnetic resonance imaging (MRI). Therapeutic treatment is segregated into radiation therapy, chemotherapy, and hormone therapy. Surgery is further divided into hysterectomy and lymphadenectomy. Amongst treatment, therapeutic treatment segment is expected to account for largest share of the market owing to the ongoing research and development regarding improvement in the treatments for uterine cancer. Surgery is expected to experience significant growth over the forecast period 2019–2026.

Based on end user

The market is segmented into hospitals, diagnostic centers, drug stores, online pharmacies, and other end users. Hospitals segment is expected to dominate the market and grow swiftly owing to the advancements in the hospital infrastructures and services. Effective treatment and diagnosis in hospitals is the other factor expected to fuel the market growth over the forecast period 2019–2026.

Regional Analysis

In terms of region the global uterine cancer market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa (LAMEA).

North America is expected to account for largest share of the market owing to the high prevalence of the uterine cancer in the region. According to the national cancer institute, over 63,230 cases of uterine cancer were registered in 2018 in the U.S. Along with this, rising awareness regarding uterine cancer and subsequent treatment options is the other factor which is expected to forecast period 2019–2026.

Europe is expected to account for significant share of the global uterine cancer market owing to the presence of global major players in the region. According to the new research by Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, in the U.K, new cancer drug Tisotumab Vedotin (TV) has shown promising results when tested on drug resistant cancer patients and 7% of the endometrial cancer tumors stopped growing and started shrinking. Ongoing research and development regarding early diagnosis of the uterine cancer is expected to boost the market growth during the forecast period 2019–2026.

Asia Pacific uterine cancer market is forecasted to experience the fastest growth during the forecast period 2019–2026. Growth of Asia Pacific market is attributed to the constantly growing geriatric population and high prevalence of uterine cancer in the region. Availability of advanced diagnostic laboratories and improved healthcare infrastructure are some of the other factors expected to positively influence the market growth over the forecast period 2019–2026.

Latin America and the Middle East & Africa are expected to account for least share of the global uterine cancer market. Poor healthcare infrastructure in the Latin America and Low healthcare expenditure in Africa are the key factors for slow growth of the market.

Uterine Cancer Market Regional Analysis
Regional Growth Insights Download Free Sample

Top Key Players of Uterine Cancer Market

  1. Novartis AG
  2. Merck & Company Inc.
  3. R-Pharm-US LLC.
  4. Actiza Pharmaceutical Private Limited
  5. Pfizer Inc.
  6. United Biotech Pvt Ltd
  7. Bristol-Myers Squibb Company
  8. Elder Pharmaceuticals Ltd
  9. Par Pharmaceutical Companies Inc.
  10. AstraZeneca Plc.

Report Scope

Report Metric Details
CAGR 4.7%
Forecast Period 2023-2031
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered
  1. By Type
    1. Endometrial Adenocarcinoma
    2. Adenosquamous Carcinoma
    3. Papillary Serous Carcinoma
    4. Uterine Sarcoma
  2. By Treatment
    1. Diagnosis
      1. Pelvic Examination
      2. Endometrial Biopsy
      3. Transvaginal Ultrasound
      4. Computed Tomography (CT or CAT) Scan
      5. Magnetic Resonance Imaging (MRI)
    2. Therapeutic Treatment
      1. Radiation Therapy
      2. Chemotherapy
      3. Hormone Therapy
    3. Surgery
      1. Hysterectomy
      2. Lymphadenectomy
  3. By End User
    1. Hospitals
    2. Diagnostic Centers
    3. Drug Stores
    4. Online Pharmacies
    5. Other End Users
Geographies Covered
  • North America
  • Europe
  • APAC
  • Middle East and Africa
  • LATAM

Uterine Cancer Market Segmentation

By Type

  • Endometrial Adenocarcinoma
  • Adenosquamous Carcinoma
  • Papillary Serous Carcinoma
  • Uterine Sarcoma

By Treatment

  • Diagnosis

    • Pelvic Examination
    • Endometrial Biopsy
    • Transvaginal Ultrasound
    • Computed Tomography (CT or CAT) Scan
    • Magnetic Resonance Imaging (MRI)
  • Therapeutic Treatment

    • Radiation Therapy
    • Chemotherapy
    • Hormone Therapy
  • Surgery

    • Hysterectomy
    • Lymphadenectomy

By End User

  • Hospitals
  • Diagnostic Centers
  • Drug Stores
  • Online Pharmacies
  • Other End Users

By Region

  • North America (U.S. and Canada)
  • Europe (France, Italy, Germany and Rest of Europe)
  • Asia-Pacific (India, South Korea, China, Japan and Rest of Asia-Pacific)
  • LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Frequently Asked Questions (FAQs)

What is the growth rate for the Uterine Cancer Market?
Uterine Cancer Market size will grow at approx. CAGR of 4.7% during the forecast period.
Some of the top industry players in Uterine Cancer Market are, Novartis AG, Merck & Company INC., R-Pharm-US LLC., Actiza Pharmaceutical Private Limited, Pfizer Inc., United Biotech Pvt Ltd, Bristol-Myers Squibb Company, Elder Pharmaceuticals Ltd, Par Pharmaceutical Companies INC., AstraZeneca Plc., etc.
In the Uterine Cancer Market, North America has established itself as the market leader with a significant market share.
The Europe region has experienced the highest growth rate in the Uterine Cancer Market.
The global Uterine Cancer Market report is segmented as follows: By Type, By Treatment, By End User
Price Starts From
USD 995

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report
Want to learn more about recent trends and data ?
They Already Trust Us :
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Johnson & Johnson
Need Assistance?
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

Report Benefits

  • Develop business strategies by understanding the trends shaping and driving the Market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track sales in the global and country-specific Market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Report Snapshot
Looking For Custom Report ?
Check Our License Options :

As featured on :

clients
Trusted by Fortune 500
Over 30000+ subscribers